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Chapter 1: Introduction 
1.1 HIV-1 Viral Infection 
According to estimates by the CDC, as of 2011 there were more than 1.2 million people living 
with HIV in the United States. The risk of HIV infection continues to be a serious public health 
concern; over the past two decades, incidence of HIV infection has stabilized at approximately 
50,000 new infections per year in the US. Of those infected, men who have sex with men (MSM), 
African Americans and those of Latin American descent, are disproportionately affected. In the 
rest of the world, HIV infection also remains an issue, with about 2.1 million new cases of HIV 
being reported in 2013. There are an estimated 35 million people living with HIV around the 
world, with sub-Saharan Africa most heavily affected by the disease 
[CDC.gov/HIV/statistics/overview].  
 
1.2 HIV-1 Protease 
HIV-1 protease (PR) is a 99 amino acid homo-dimeric enzyme. The two monomers of the PR 
form a central active site channel which contains the catalytic residues Asp 25 and Asp 25’.  HIV 
PR is responsible for the maturation of virions by cleaving the Gag and GagPol polyprotein 
precursors into functionally active proteins [1][2]. The Gag precursor is cleaved into the structural 
proteins including the matrix, capsid, nucleocapsid, and spacer peptides p1, and p2. The Pol 
precursor is cleaved into the viral enzymes protease, reverse transcriptase and integrase [1]. As 
HIV-1 PR plays such an essential role in the HIV-1 viral life cycle, it has become an attractive and 
successful target for drug development.  
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1.3 HIV-1 PR Inhibitors 
To combat HIV infection, highly active anti-retroviral therapy (HAART) remains the standard 
of care, with protease inhibitors (PIs) playing an essential role. HAART typically consists of a 
cocktail of anti-retroviral drugs including two nucleoside reverse transcriptase inhibitors (NRTIs), 
along with either a non-nucleoside reverse transcriptase inhibitory (NNRTI) or a PI. HAART 
combinations including PIs have been typically more effective than combinations that do not 
include PIs, and monotherapies [3].  
There are currently nine PIs approved for use by the FDA: Ritonavir (RTV), Lopinavir (LPV), 
Atazanavir (ATV), Darunavir (DRV), Saquinavir (SQV), Indinavir (IDV), Nelfinavir (NFV), 
Tipranavir (TPV) and Fosamprenavir (FPV). PIs inhibit PR by binding to the active site residues, 
competing with the natural substrate peptides. PIs have been designed to mimic the natural 
transition state of the peptide, where the PI hydroxyl interacts with the carbonyl of Asp 25 and 
Asp 25’ in the HIV PR active site, thus inactivating the enzyme [4]. Unfortunately, drug resistance 
PR mutations have been associated with each PI. Because of their similar structure, and mechanism 
of action, it is common for cross resistance to occur between PIs , resulting in treatment failure 
[4][5]. Mutations in regions flanking the binding pocket of HIV-1 protease are typically seen in PI 
resistance, because in this area the mutations will interfere with inhibitor binding but not Gag and 
GagPol binding [6]. 
1.4 HIV-1 PR and Drug Resistance 
Though PIs have been effective at reducing HIV related deaths, resistance to these drugs occurs 
when mutations in the PR lead to reduced binding affinity of the PR for the inhibitor, while 
interactions between the PR and substrate remain [7]. Thus, inhibitors are unable to bind and block 
enzyme activity, while substrate continues to bind and be cleaved by the PR. 
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Mutations which lead to PI resistance occur in large part due to the highly error prone reverse 
transcriptase and its lack of proof reading ability. As PR mutations accumulate in the viral 
population, there is an increase in genetic diversity; an evolutionary advantage for the virus which 
under drug induced selective pressure allows for PR with these mutations to proliferate if they 
confer a survival advantage in the presence of a PI. Non-compliance with HAART therapy can 
accelerate the process of selecting drug resistant mutants [5].  
These mutations affect drug-PR interactions in a variety of ways, depending on the type of 
mutation present. Amino acid substitutions in the PR active site, called primary mutations, account 
for the majority of PI resistance and directly alter drug-PR interactions, resulting in the inability 
of the drug to bind and efficiently block enzyme function [5][7]. Primary mutations may result in 
cross-resistance due to PIs being similar in structure, but they may also reduce the catalytic activity 
of the PR as well [7]. Resistance mutations may also occur at the dimer interface disrupting the 
interactions between the two monomers. Changes in the interaction network between the two 
monomers of PR, could result in dissociation of the dimer and release the PI from the active site 
[5]. Mutations distant from the active site have also been shown to confer resistance by altering 
interactions indirectly between necessary water molecules, and enzyme dynamics. These distant 
mutations may also in some ways modulate the activity of major resistance mutations in ways that 
are not immediately apparent [5].  Mutations in the PR are not always substitutions, insertions have 
been documented in the literature, though their mechanism of action and the role they play in PI 
resistance remains unclear. 
 
  
 
 4
1.5 HIV-1 PR Insertion Mutations 
Of all mutations, insertions in the HIV protease remain among the most understudied in the 
literature. Protease insertions typically occur as repeating sequences of neighboring amino acids, 
and the proposed mechanism by which insertions are formed is thought to be due to slipping of 
the reverse transcriptase [8][9]. Insertions occur at many different positions in the HIV protease, 
but tend to occur near external loops and turns, especially in larger insertions of more than five 
amino acids. Insertions in the PR are thought to be rare, in one study comprising only 0.1% of 
mutations in a sample population between 1999-2000 [8]. Insertions themselves are not shown to 
have an effect on resistance to PIs. A 2001 study showed that no real difference existed in drug 
susceptibility between multi-drug resistant (MDR) isolates containing an insertion, and non-
insertion containing isolates [10]. This suggests that the PI resistance mutations (rather than the 
insertion) were responsible for decreased susceptibility to PIs [10]. However, some evidence 
suggests that insertions may in fact be compensatory to resistance mutations . These data suggest 
that MDR proteases containing an insertion show a boost in substrate cleavage, and replicative 
capacity [8].  
1.6 HIV-1 PR Clinical Isolate 
At present, there are no modeling studies of an insert-containing PR isolate. We report a 
detailed modelling study of an isolate containing a 5-residue insertion between codons 28 and 29 
(MDR/28). This isolate was obtained from a patient at the Wayne State University Infectious 
Disease Clinic in Detroit, MI. The patient is poorly adherent with antiretroviral therapy. MDR/28 
is the first isolate at this facility to contain an insertion of this size. Additionally, this isolate 
displays reduced replicative capacity compared to the WT virus, as it is expected most mutations 
will reduce replicative capacity. To structurally characterize the impact of the MDR/28 insertion, 
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a homology model was created and compared to a wild-type crystal structure and a protease 
model containing the MDR mutations with the insert removed. Each protease model was then 
docked with protease inhibitors (PI) and cleavage peptide CA/p2 [11]. Molecular dynamics 
simulations were performed for each of the complexes using NAMD [12]. 
Chapter 2: Materials and Methods 
2.1 Phenotypic and Genotypic Reports 
 Phenotypic reports regarding the mutant MDR/28 PR were obtained from a Phenosense ® 
HIV drug resistance test, ordered by the Detroit Medical Center [13]. Phenosense provides a 
quantitative measurement of how well the clinical isolate responds to antivirals, including 
nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors 
(NNRTIs) and protease inhibitors (PIs). This report also includes replicative capacity data.  
 Viroseq ® HIV-1 genotyping system was used at the Detroit Medical Center in order to 
obtain genotypic data on the clinical isolate PR [14]. This system screens against software to 
identify known resistance mutations.  
2.2 Homology Modeling 
 A homology model of MDR/28 PR was created using Schrödinger Prime [15].  2O4S.pdb 
was obtained from the Protein Data Bank (rcsb.org) and was used to build the model. 2O4S 
exhibits 82% sequence identity to the insertion isolate MDR/28, and was chosen as it provides the 
highest sequence homology available for all PR structures in dimer form [16]. A model was created 
of MDR PR, with the insertion removed, also using 2O4S.pdb as a template.  
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2.3 Molecular Dynamics Simulation 
2.3.1 Protease Complex Preparation 
 Sixteen systems underwent molecular dynamics simulations, including apo structures of 
WT HIV-1 PR, MDR/28 PR, and MDR PR, as well as all PR models with ligands bound. The 
ligands used for the simulations were DRV, ATV, LPV, SQV, and CA/p2. To obtain proper 
coordinates for the ligands, the homology models and WT PR were aligned to pdb entries 4DQV 
(DRV) [17], 2NNP (SQV) [18], 3EKY (ATV) [19], 4L1A (LPV) [20], and 3OUD (CA/p2) [21], 
using Pymol to obtain proper coordinates [22].  
2.3.2 System Preparation 
 The preparation of the system for MD simulation was carried out using Visual Molecular 
Dynamics software (VMD v.1.9.2) [11]. The PR complexes as well as apo structures were placed 
in a 12 Å TIP3P water box and were then neutralized with 0.15 M MgCl2. Simulations were 
performed for 40 ns using NAMD (e) V 2.9 [23] and  CHARMM force field 36 [24] to set 
parameters. The Particle Mesh Ewald (PME) method was used to calculate long range coulomb 
interactions. Temperature was maintained at 300 K using Langevin dynamics and pressure 
maintained at 1 atm using the Nose-Hoover Langevin piston method. All simulations were run 
using one of two different computing clusters, the Wayne State University Grid 
(www.grid.wayne.edu) or Stampede at the Texas Advanced Computing Center 
(http://www.tacc.utexas.edu).  
2.4. Structural Analysis 
 Distance measurements and secondary structural analysis were carried out using VMD 
[11]. Analysis of the PR active site volume was carried out using Caver analyst, to visualize and 
measure the active site channel over the 40ns trajectory [25]. The volume of each tunnel was 
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averaged for the whole simulation. To study the interactions between the PR and peptide, Ligplot+ 
was used to visualize hydrogen bonds and VdW interactions [26]. These too were averaged for 
each PR complex over the length of the MD trajectory. 
2.5 Docking and Affinity Estimation 
 In order to quantify a difference in binding affinity between the WT PR and mutant 
MDR/28, MM-GBSA calculations were performed using the Prime function of Schrodinger 
software [27]. MM-GBSA method calculates the free energy of binding through the use of 
molecular mechanics and implicit solvation models, where the binding energy=∆E(complex)- ∆E 
(ligand)-∆E(substrate). [27]. In preparation for MM-GBSA analysis, the WT, MDR/28 and MDR 
PR and ligands were prepared using the protein preparation wizard and ligprep functions 
(Schrodinger release 2014) [28], respectively. Subsequently, induced fit docking with Glide was 
performed to accommodate various ligands in each PR active site [29]. The resulting Glide poses 
were used as input for the MM-GBSA affinity estimation, and their energy scores were averaged 
for each ligand.  
 
Chapter 3: Results 
3.1 MDR/28 HIV PR mutant exhibits resistance to multiple protease inhibitors and 
displays reduced replicative capacity  
 Phenosense® susceptibility testing of MDR/28 revealed full or partial resistance to the 
following PIs: atazanavir (ATV/r), amprenavir (AMP/r), indinavir (IDV/r), tipranavir (TPV), and 
nelfinavir (NFV) (Table 1). It was also determined in a Phenosense® replicative capacity assay 
that in the absence of inhibitors the isolate MDR/28 functioned at a reduced replicative capacity 
compared to WT (Fig 2).   
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 Genotyping with Viroseq® showed MDR/28 contained resistance mutations impacting 
the affinity of the PIs IDV, LPV, fosamprenavir (FPV), as well as conferring possible resistance 
to TPV, DRV, and ATV. Saquinavir (SQV) was the only inhibitor for which there were no 
known resistance mutations present (Table 1). A list of resistance mutations found in MDR/28 
and their contributions are listed in Fig 1.b.  
 
 
3.1.1 Discussion 
 Phenotype and genotype testing revealed that the clinical HIV-1 PR isolate was multi-
drug resistant (MDR) and contained a five residue insertion at position 28 of the HIV-1 PR gene. 
Comparison between phenotypic and genotypic data showed that though the two assays 
agreed relatively well, there were some drugs for which the phenotypic and genotypic 
resistance data differed (Table 1). For our purposes, we used the phenotypic results in order to 
choose drugs to complex with our PR models. Genotypic reports tend to be more predictive of 
future drug resistance, as they detect mutations which may only cause resistance if 
accompanied by other mutations that modulate their activity.  We are interested in the clinical 
outcome [i.e. the phenotypic data]. We determined that DRV, ATV, and LPV were the PIs most 
Table 1: Phenotypic and genotypic susceptibility data. The phenotypic and genotypic 
resistance data provided by Phenosense and Viroseq reports are summarized in 
the table above. For detailed genotypic information see the resistance mutation key 
for MDR/28 in Fig 1. 
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clinically relevant at the current time and as such were chosen for simulation. SQV was used as 
well as it is the only PI that MDR/28 was shown to be susceptible to in both assays.  
 
1.a.  
(1)PQITLWQRPVVTIKVGGKLKEALLDTGADDTILDDTILEEMDLPGRWKPKIIGGIGGFLRVRQYDQIPIEICG
HKVIGTVVVGPTPMNIIGRNLLTQLGCTLNF(104) 
 
1.b. 
 
Mutation Requires additional mutation Possible 
resistance 
Resistance Resistance 
countered 
L10V TPV,IDV,SQV,DRV,ATV,NFV,FPV LPV   
V32I TPV,IDV,LPV,DRV,ATV,NFV,FPV    
M46I TPV, IDV,LPV,ATV,FPV NFV   
I54L IDV,SQV,LPV,DRV,ATV NFV FPV  
A71V TPV,IDV,SQV,LPV,ATV    
L76V DRV IDV,LPV FPV TPV 
V82M TPV,IDV,LPV,ATV,NFV,FPV    
 
 
 
 
Fig 1. Sequence of the MDR/28 isolate and resistance mutations. (a): The amino acid sequence for 
MDR/28 PR is shown above, with the insertion residues colored in purple. The MDR mutations are 
colored in red. (b): The genotype of MDR/28 clinical isolate is summarized below according to the 
Viroseq HIV-1 genotyping system report.  
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3.2 The active site volume of MDR/28 is increased compared to wild type 
The active site channel of MDR/28 initially appeared to be smaller in volume than WT PR 
(Fig 3.a). To confirm this observation, Caver analyst was used to compute the length and 
bottleneck radius of the active site channel of each PR over the course of the simulation, showing 
that in fact MDR/28 active site volume increases as the simulation progresses [25](Fig 3.b). From 
this, we calculated the average total volume of each channel, MDR/28 was shown to have a greater 
active site channel volume than WT PR by about 16%, contrary to our initial observation (Fig 3.c).  
The solvent accessible surface area (SASA) of the catalytic residues Asp 25 and Asp 25’ 
was measured using the VMD timeline plugin [11]. The SASA of MDR/28 was observed to be 
slightly higher than that of WT by 3 Å2 (Fig 4).  
3.2.1 Discussion 
 Previous studies have shown that an increase in the PR active site volume results in a 
weaker binding to substrate, due to the loss of important interactions between the PR and 
Fig 2. Viral replicative capacity of MDR/28.  The replicative capacity of MDR/28 
mutant virus is shown as compared to a WT virus. MDR/28 displayed an average 
replicative capacity of only 29% of WT.  
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substrate [30]. It follows that the increased active site volume of MDR/28 PR when compared to 
WT, observed in our analysis, will result in a loss of interactions between active site residue side 
chains and substrate.  
It is worth noting that the increased active site channel volume was seen as a result of the 
MD simulation, wherein one of the flap tips of MDR/28 was observed to curl back on itself. It is 
possible that this curling back of the flap may result in the spike seen in active site volume from 
the 29th to 32nd ns (Fig 3.b).  For this reason, we calculated the SASA, and although there is only 
a 3 Å2 increase in the binding site (surface area) of MDR/28, this may be sufficient to disturb 
interactions between PR and substrate (Fig 3.c). MDR PR that exhibit only a 3.0 Å2 increased 
active site volume have been associated with high level resistance over WT PR [31]. For this 
reason, we assert that because MDR/28 displays a predicted expansion of SASA area and active 
site volume, these may lead to a loss of important interactions with substrate.  
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3.a 
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3.b  
 
  
3.c 
  
 
 
 
 
 
Protease Total Average Volume (Å^3) 
WT 340 
MDR/28 359 
Fig 3. The active site volume of MDR/28 relative to WT. (a): From left MDR/28 PR is shown in cyan, 
with its corresponding channel volume colored in blue. On the right WT PR is shown in green with 
its channel volume in magenta. The channels were calculated using the caver plugin for Pymol, and 
represent the active site volume post energy minimization. (b):  The average active site volume over 
the course of the 40ns simulation is shown. (c): The total average volume for the active site channels 
is presented, this represents the average for all channels over 40ns.   
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4.a 
 
 
 
4.b 
PR AVG SASA 
MDR/28 285 
WT 282 
 
 
 
 
3.3 Peptide binding to MDR/28 is shifted to one side of the active site 
In a superimposed view of MDR/28 and WT PR in complex with the CA/p2 peptide, the 
peptide appeared to be displaced in the MDR/28 active site after energy minimization was 
completed (Fig 5). To quantify this displacement,  the distance between the PRs was measured at 
the scissile bond carbon using VMD [11].  MDR/28 had shifted 2.9 Å to one side of the active site 
compared to the WT complex. 
Fig 4. Solvent available surface area for catalytic residues.  (a) The solvent accessible 
surface area is shown over the course of a 40ns simulation for residues Asp 25 and 
Asp 25’ of MDR and WT PR. (b) The average SASA for each PR is compared.  Values 
were determined to be statistically significant by one-way ANOVA p < 0.05.  
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 In order to confirm that this displacement of the peptide was consistent over the entire 40ns 
MD trajectory, measurements were taken for each of the PR complexes, measuring the distance 
from each Asp 25 gamma carbon (for ease of measurement) to the scissile carbonyl carbon of the 
peptide over the course of the entire simulation (Fig 6). This analysis revealed that as the 
simulation progressed, the peptide in the MDR/28 complex moved further away from Asp 25. The 
initial distance was 5.23 A at the beginning of the simulation and increased to 8.74 Å by the end, 
averaging 8.60 Å for the whole simulation. In contrast, in the WT complex the CA/p2 peptide was 
seen to move from 4.71 Å to 5.54 Å away from Asp 25, averaging only 5.36 Å.  
Fig 5. Superimposed view of MDR/28 and WT peptides. Above view of superimposed 
MDR/28 PR (cyan) and WT (green) PR in complex with peptide CA/p2. The peptide MDR/28 
shown in blue is displaced towards one side of the active site when compared to the WT 
peptide in magenta. This figure is a representation of frame 21 of the trajectory. 
 
28 
 
 
 
 
 
3.3.1 Discussion 
The migration of the peptide away from catalytic residues that is observed in the MDR/28 
complex is a result of missing interactions (to be determined in later analysis) which are needed to 
allow peptide to bind in the active site for catalysis. It is known that the recognition and binding 
of peptide in the PR active site is largely dependent on the shape and size of the peptide in question 
[32]. An increased PR active site may not correctly recognize the peptide thus allowing it to move 
out of the active site without being cleaved. There is another structural feature that may account 
for a lack of interactions between PR-and peptide: secondary structure.  
 
 
 
Fig 6. Distance measurements between the peptide and catalytic residue. The distance 
from the CA/p2 scissile carbonyl to the gamma-carbon of Aspartate 25 over the course of 
20,000 frames is shown. MDR/28 in blue, WT in orange. The peptide appears to be moving 
increasingly further from the catalytic residue. 
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3.4 The MDR/28 insertion causes local secondary structural changes  
In order to see if any secondary structural changes were induced by the insertion that could 
account for lost interactions, Ramachandran analysis was performed for residues 25 through 35. 
Residues were chosen that flank the insertion on both sides, omitting the insertion residues 
themselves. This analysis revealed that compared to WT PR, MDR/28 shows a marked change in 
secondary structure at residues 29 and 30 (Fig 7). At residue 29 a right-handed alpha helix 
conformation normally present in WT is changed to a beta sheet conformation in MDR/28. Residue 
30 displays the opposite effect, with the normal beta sheet conformation being transiently changed 
to alpha helical over the course of the simulation. No other residues which surrounded the insertion 
showed a change in secondary structure. 
 MDR PR, which functioned as a control, showed no change in secondary structure when 
compared to WT. This is evidence that the five residue insertion at residue 28 transiently affects 
the secondary structure of neighboring residues. 
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3.4.1 Discussion 
In addition to increased active site volume, the changes in secondary structure at residues 29 
and 30 may contribute to the loss of interactions in MDR/28 compared to WT PR. Prior research 
illustrates that peptide interactions with PR residues 29 and 30 are responsible for the specificity 
of the PR for CA/p2 peptide cleavage site [31]. These residues are also known to make hydrogen 
bonds to the backbone of all cleavage peptides and residue 30 is known to contribute to specificity 
Fig 7.: Secondary structural analysis of insert flanking residues. Ramachandran plot analysis of 
secondary structure for each PR, residues 28-31 are pictured above. The residues were chosen to 
analyze changes in PR structure on either side of the insertion sequence, and the insertion itself was 
not included. Notice the change in secondary structure from WT to MDR/28 at residues 29 and 30 in 
particular. 
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by making side chain hydrogen bonds to either Glu or Gln residues present in peptides CA/p2, 
p2/NC, and p1/p6 [30]. The changing of secondary structure of these residues could have 
implications in reducing the number of interactions between PR and peptide.  
 
3.5 Hydrogen bonds and VdW interactions are lost in MDR/28 compared to WT 
 To investigate if the previous structural changes (increased active site and secondary 
structural changes) contribute to a loss of interactions between the PR and peptide, Ligplot+ 
analysis was used. Every 4ns throughout the MD simulation, the hydrogen bonds and VdW 
interactions were calculated for each PR complex, and the total interactions present at each frame 
measured across the whole simulation were averaged. Any interactions which were lost in 
MDR/28 compared to WT were noted (Table 2). MDR/28 PR lost a total of four hydrogen bonds 
to the peptide, and five VdW interactions which were present in the WT complex. 
 
Hydrogen bonds lost VdW interactions lost 
Asp 30 Val 82 
Gly 48 Val 32 
Gly 49 Met 46 
Ala 28 Arg 8 
 Asp 29 
 
 
 
Table 2. Interactions lost between MDR/28 PR and peptide. The lost interactions of MDR/28 
with peptide are shown when compared to WT. Both hydrogen bonds and VdW interactions 
were investigated over 40ns.  
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3.5.1 Discussion 
 Of interest among the lost interactions are VdW interactions to residue 29 and hydrogen 
bonding to residue 30. As previously stated these two residues are important in peptide recognition 
and specificity. The fact that these residues are altered in MDR/28, and interactions are lost to 
them is further evidence that the insertion has induced a change in the PR which results in its 
inability to bind tightly to substrate. Gly 48 is likewise considered a conserved bond among all PR 
and Gagpol interactions, and is also missing in MDR/28. The loss of such important interactions 
implies that binding affinity between PR and substrate may be negatively affected in MDR/28, and 
thus lead to a reduced replicative capacity. 
 
3.6 MM-GBSA binding affinity data shows MDR/28 has decreased affinity for substrate and 
ligands  
 A loss of interactions between the PR and peptide suggests decreased binding affinity. Data 
from MM-GBSA calculations showed that ligands were predicted to bind more tightly to WT PR 
than MDR/28 PR (Fig 8). The difference in binding affinity that was observed between MDR/28, 
MDR and WT PR was determined to be statistically significant by single factor ANOVA for all 
ligands. All PIs and CA/p2 in complex with MDR/28- displayed a decreased binding energy of at 
least 26% (for SQV) and up to 36% (for LPV) (compared to WT). 
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3.6.1 Discussion 
 MM-GBSA analysis predicted MDR/28 has a worse affinity for substrate than WT, as our 
previous data had suggested. Interestingly MDR/28 has a better binding affinity than the MDR 
control, suggesting that there is a compensatory effect to the insertion. The decrease in binding 
affinity of MDR/28 as a result of lost interactions, may result in the displaced peptide and its 
subsequent migration from the catalytic residues seen during the 40ns MD simulation.  
 
 
 
Fig 8.: Binding affinity data for PR complexes. The normalized binding energy of PR complexes was 
determined using the MM-GBSA function of Schrodinger Prime software. The binding energy data is 
a normalized average for each complex, as each drug had numerous possible poses in the PR active 
site. For each ligand p < 0.05.  
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Conclusions 
 Our goal was to elucidate the mechanism of reduced replicative capacity in a mutant-
bearing PR with an insertion at residue 28. Structural changes in the PR introduced by the insertion 
(such as the increased active site volume and secondary structural changes of residues 29 and 30), 
resulted in a loss of hydrogen bonds and VdW interactions between the PR active site and the 
peptide CA/p2. The loss of necessary contacts leads to decreased affinity of MDR/28 for peptide, 
which allows for the displacement of the peptide in the active site and its migration away from the 
catalytic residues. Without proper interactions between the PR and peptide, the peptide is unable 
to be held in the proper conformation for cleavage, and mature proteins will not result. This could 
result in a reduced replicative capacity for the virus. No mechanism of the effect of the insertion 
(rather than other MDR mutations) on PIs was seen in the data.  
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ABSTRACT 
A FIVE RESIDUE INSERTION BETWEEN CODONS 28 AND 29 OF THE HIV-1 
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HIV-1 protease (PR) is a 99 amino acid protein responsible for cleavage of the viral 
polyprotein. We have identified a novel clinical isolate, MDR/28, which contains a five residue 
insertion between codons 28 and 29 of a multi-drug resistant (MDR) PR. This clinical isolate 
displays reduced viral replicative capacity compared to the wild-type. As opposed to drug-
resistance mutations, studies on insertions remain largely underrepresented in the literature, 
and the consequences of such insertions are largely unknown. To understand the mechanism 
leading to reduced replicative capacity, three PR models were created and subjected to 40ns 
molecular dynamics simulations: MDR/28, wild type, and MDR PR. In addition, PR inhibitors (PI) 
atazanavir (ATV), darunavir (DRV), lopinavir (LPV) and saquinavir (SQV), as well as cleavage 
peptide CA/p2 were docked to the three models. The MDR/28-PI complexes displayed decreased 
binding affinity when compared to WT complexes, likely due to an increased active site cavity 
volume and altered secondary structure at residues local to the insertion mutant. Additionally, 
in the active site of MDR/28 the predicted binding mode of the CA/p2 peptide did not include 
contact with the catalytic residues, and migrated from that position, a behavior not 
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seen with any tested PIs or with either of the other PR models. These structural changes 
produced by the insertion suggest a mechanism for reduced replicative capacity of the mutant 
virus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30 
 
AUTOBIOGRAPHICAL STATEMENT 
Cathy McLeod is a graduate student at the Wayne State University School of Medicine. She 
received a bachelor’s degree in biology from the University of Detroit Mercy. Her research 
interests include viral drug targets, and structural biology. Her future directions include pursing 
continuing education and employment in the private sector.  
